PHILADELPHIA, Pa. June 20 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) today announced that the United States Food and Drug Administration has extended the priority review period for PROMACTA(R) (eltrombopag) for the short-term treatment of previously treated patients with chronic idiopathic thrombocytopenic purpura, as they require more time to review the application. The Prescription Drug User Fee action date has been extended to September 19, 2008.
On May 30, the Oncology Drugs Advisory Committee unanimously voted, 16-0, that eltrombopag demonstrated a favorable risk-benefit profile for the short-term treatment of patients with chronic idiopathic thrombocytopenic purpura, or ITP.
GSK will continue to work with the FDA towards the approval of eltrombopag in order to provide physicians and chronic ITP patients with a novel option for treating this difficult disease.
About Promacta(R) (Eltrombopag)
Eltrombopag, a novel oral thrombopoeitin (TPO) receptor agonist, if approved, would be the first oral short-term treatment of previously treated patients with chronic ITP to increase platelet counts and reduce or prevent bleeding. In the pivotal studies, the most common adverse events observed in patients taking eltrombopag were headache, common cold, and nausea.
GlaxoSmithKline -- one of the world's leading research-based
pharmaceutical and healthcare companies -- is committed to improving the
quality of human life by enabling people to do more, feel better and live
longer. For company information, visit GlaxoSmithKline at http://www.gsk.com.
US Media inquiries: Jeff McLaughlin 1 919 483 2839
Mary Anne Rhyne 1 919 483 2839
Nancy Pekarek 1 215 751 7709
UK Media inquiries: Claire Brough 44 20 8047 5502
Philip Thomson 44 20 8047 5502
Alice Hunt 44 20 8047 5502
Gwenan White 44 20 8047 5502
US Analyst/Investor inquiries: Frank Murdolo 1 215 751 7002
Tom Curry 1 215 751 5419
UK Analyst/Investor inquiries: David Mawdsley 44 20 8047 5564
Sally Ferguson 44 20 8047 5543
Gary Davies 44 20 8047 5503
Copyright©2008 PR Newswire.
All rights reserved